Development Manager at RoosterBio, Inc.
Washington D.C. Metro Area
ATCC
Director, BioProduction
June 2012 to Present
Lonza
Sr. Manager, Cell Therapy Process Development
May 2010 to June 2012
GenVec
Associate Director of Biochemistry
August 1993 to January 2009
American Cyanamid (Lederle Labs)
Protein Chemist
May 1989 to July 1993
đź“– Summary
Extensive background in all aspects of research and development of therapeutic proteins and novel vector-based vaccines.Director, BioProduction @ From June 2012 to Present (3 years 7 months) Sr. Manager, Cell Therapy Process Development @ From May 2010 to June 2012 (2 years 2 months) Associate Director of Biochemistry @ Research and development of novel therapeutic drugs and vaccines. From August 1993 to January 2009 (15 years 6 months) Protein Chemist @ Studied the development of new blood vessels and methods to inhibit their growth as an approach to treat solid tumors. During this time I co-discovered the receptor for vascular endothelial growth factor, known as KDR or VEGFR2. From May 1989 to July 1993 (4 years 3 months) MS, Chemistry @ Eastern Illinois University From 1985 to 1987 Miguel Carrion is skilled in: Molecular Biology, Biochemistry, Biotechnology, Protein Chemistry, ELISA, Cell Culture, Vaccines, Biopharmaceuticals, Technology Transfer, Assay Development, Cell Biology, Lifesciences, Purification, Process Simulation, Protein Purification
What company does Miguel Carrion work for?
Miguel Carrion works for ATCC
What is Miguel Carrion's role at ATCC?
Miguel Carrion is Director, BioProduction
What industry does Miguel Carrion work in?
Miguel Carrion works in the Biotechnology industry.
Who are Miguel Carrion's colleagues?
Miguel Carrion's colleague is Michael Ph.D.
Extraversion (E), Intuition (N), Feeling (F), Judging (J)
6 year(s), 4 month(s)
Unlikely
Likely
There's 94% chance that Miguel Carrion is seeking for new opportunities
Enjoy unlimited access and discover candidates outside of LinkedIn
One billion email addresses and counting
Everything you need to engage with more prospects.
ContactOut is used by
76% of Fortune 500 companies